Research Of Erlotinib For Patients With Advanced NSCLC

Objection:To observe the effects and side effects of erlotinib,taxotere/cisplatin,gemcitabin/cisplatin in the treatment of patients with advanced non-small cell lung cancer.To evaluate the value of erlotinib in the treatment of NSCLC.materials and methods:(1) General condition of the patients:76 patients with definite diagnosed of developed non-small cell lung cancer admitted into Shandong Provincial Hospital from December 2006 to December 2008 were enrolled into our study,including 42 males and 34 females,median age 57 years(ranged 38-79 years).Some patients in early state of lung cancer,small cell lung cancer,accepted operations or radioactive therapy were excluded.They were grouped into 3 groups,groupâ… was experiment group,groupâ…¡and groupâ…¢were the controlled groups.There were no sex,age differences of the three groups.(2) Clinical treatment:The patients in groupâ… were given oral erlotinib at a dose of 150mg per day for 30 days.This was repeated at least 3 cycles.The patients in groupâ…¡were treated with taxotere+cisplatin per three weeks and repeated at least 3 cycles.The patients in groupâ…¢were treated with gemcitabin+cisplatin per three weeks and repeated at least 3 cycles.All the patients can received symptomatic treatment such as thoracentesis,paracentesis pericardii and drug which can enhance their immunity.Result:(1) Short-term effects:groupâ… 30.8%,groupâ…¡44.0%,groupâ…¢48.0%;Mediea survival time:groupâ… 9.9 months,groupâ…¡10.7 months,groupâ…¢10.9 months.(2) the clinical effects of the patients (3)side effects:There was no side effect which could not be treated.The patients can endure the side effects such as rash,diarrhea by prevent or treatment.Conclusion:1,For patients with advanced NSCLC that undergoing conventional chemotherapy,Erlotinib has the exact effect.Symptoms remission,quality of life,time to disease progression,the median survival time all similar to taxotere+ cisplatin,gemcitabin+cisplatin.So it can be used as second-line treatment.2,For the new patients whose age beyond 65,quality of life is so poor that who can't tolerant to chemotherapy,Erlotinib can be ued as first-line treatment.4,Erlotinib has good compliance and security,don't increase virulence,and extend the survival time significantly.Erlotinib is easy to take,can improve the quality of life and has fewer adverse reactions.